Navigation Links
Elan in Medical News
NEW BRUNSWICK, N.J. and DUBLIN, July 2 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ ) and Elan Corporation plc (NYSE: ELN ) today announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheime...
...ts such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, ...
Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
CORONA, Calif., March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Elan Corporation, Plc on outstanding patent litigation related to Watson's generic version of Naprelan(R)...Berger & Montague Announces Class Action Lawsuit Against Elan Corporation
PHILADELPHIA, Oct. 29 /PRNewswire-USNewswire/ -- Berger & Montague ("Berger") announced today that a class action lawsuit was filed in the United States District Court of New York on behalf of all purchasers of American Depository Shares (evidenced by American Depository Receipts) of Elan Corp...Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc
TORONTO, Oct. 26 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition") (NASDAQ: TTHI , TSX: TTH) announced the receipt of US$7.5 million representing the second half of the US$15 million upfront payment under the Company's global collaboration agreement with a subsidiary of Ela...Transition Therapeutics Announces Milestone Payment from Elan
TORONTO, Dec. 24 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (TSX: TTH; NASDAQ: TTHI), announced today that the Company will receive a US$5million milestone payment under its global collaboration agreement with a subsidiary of Elan Corporation, plc ("E...Orexigen(R) Therapeutics Announces Second Quarter 2009 Financial Results
... served as Senior Vice President of Global Safety, Regulatory Affairs and Quality for Chiron Biopharma, and in similar roles with Nektar Therapeutics, elan Pharmaceuticals and Novartis Biopharma. Jay Hagan as Senior Vice President of Corporate Development and Strategy. Jay has spent the bulk of h...FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
...le. INVEGA SUSTENNA was developed utilizing elan Drug Technologies' proprietary NanoCrystal(R) Tech...m/ . About NanoCrystal(R) Technology and elan Drug Technologies INVEGA SUSTENNA utilizes the...gy, which is a proprietary technology developed by elan Drug Technologies through...PDL BioPharma Announces Second Quarter 2009 Financial Results
...tin(R), and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-LaRoche Ltd., and sales of Tysabri(R), which is marketed by elan Corporation Plc. and Biogen Idec Inc. Royalty revenues are based on first quarter 2009 product sales by PDL's licensees and include $18.9 million for...Victory Pharma, Inc. Announces FDA Accepts MGX006 NDA for Review
...side effects Further information regarding Victory Pharma is available at www.victorypha r ma.com . NAPRELAN (R) is a trademark of elan Corporation, plc. ......ts such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, ...
Elan in Medical Technology
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
.... INVEGA(R) SUSTENNA(TM) was developed utilizing elan Drug Technologies' proprietary NanoCrystal((R)) Te... About NanoCrystal ((R)) Technology and elan Drug Technologies INVEGA(R) SUSTENNA(TM) util...gy, which is a proprietary technology developed by elan Drug Technologies through......NILIN(R) monoclonal antibody platform to Wyeth and elan Pharma International Ltd. The license grants rights to Wyeth and elan under Intellect's patents with respect to the deve...onoclonal antibody intended to treat AD. Wyeth and elan are currently testing Bapineuzumab in several thou...
... to Drug Discovery for PD, a collaboration made possible by co-funding from elan (NYSE: ELN ); and the industry-exclusive Therapeutics Development Initiati...tiative. Novel Approaches to Drug Discovery for PD A collaboration with elan Pharmaceuticals, Inc. Total available funding: $1.5 million Deadline: 6...
...y SODAS(R) (Spheroidal Oral Drug Absorption System) technology developed by elan Corporation, where 50% of the dose is released immediately and the remainin...usive worldwide (except Canada) royalty and manufacturing agreement between elan Corporation, plc, and Novartis Pharma AG. References 1. Concerta(R) is ...
...euzumab being developed independently by Wyeth and elan Pharma International Ltd. (Elan) in that it binds ...nical trials. The recent announcement by Wyeth and elan of positive Top Line Phase 2 data in a subset of p...has granted a royalty-bearing license to Wyeth and elan Pharma International Ltd. (Elan) regarding patents...
September is National Pain Awareness Month
...ists for those who are suffering in the form of a sea snail. Researchers at elan Pharmaceuticals, Inc., a wholly-owned subsidiary of elan Corporation, plc, have harnessed the venom of the Conus magus sea snail int......IRE)--May 3, 2007 - Biogen Idec (NASDAQ: BIIB) and elan Corporation, plc (NYSE: ELN) announced today that ... company, please visit www.biogenidec.com. About elan elan Corporation, plc is a neuroscience-based biotechno...
Archemix Announces Completion of Phase 1 Trial of ARC1779
...g to aptamers has enabled it to form numerous collaborations with biotechnology and pharmaceutical collaborators, including Merck Serono, Pfizer Inc., elan Pharma, Nuvelo, Inc., Antisoma plc., and Regado Biosciences. For more information, please visit www.archemix.com. Contact Media Yates and Asso...Elan in Biological Technology
Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
DUBLIN, May 4 /PRNewswire/ -- Circ Pharma Limited ("Circ Pharma") and Elan Corporation plc ("Elan") today announced that they have entered into a Development Agreement to develop a chronotherapeutic formulation of Tramadol for the treatment of moderate to moderately severe pain. The pro...RADNOR, Pa., Dec. 11 /PRNewswire/ -- The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP: Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of New York on beha...
Azur Pharma and Elan Corporation (NYSE: ELN) Sign Agreement to Develop a Once-Daily Clozapine
DUBLIN, November 10 /PRNewswire/ -- Azur Pharma Limited ("Azur") today announced that it has entered into an agreement to develop and commercialise once-daily formulations of clozapine using Elan Corporation plc's ("Elan")(NYSE: ELN ) proprietary drug delivery technologies, including its NanoC...NEW YORK, May 19 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease (AD), announced today that it has entered into...
Promise of revolutionary orally-administered drugs to combat Alzheimer's began journey 8 years ago "Finding a needle in a haystack - 4 molecules out of a million" NEW YORK, Aug. 6 /PRNewswire-USNewswire/ -- New therapeutics funded by the Alzheimer's Dr...
...VIENNA, Austria, July 14 /PRNewswire-FirstCall/ -- elan Corporation, plc (NYSE: ELN ) and Wyeth (NYSE: ...ternational. Editors Note: The following elan and Wyeth abstracts were also presented at ICAD: ...usions or hallucinations. About the elan and Wyeth Collaboration The Alzheimer's Immu...
...nanomedicine market include Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corporation, Crucell N.V., Flamel Technologies S.A., elan Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics, Novavax Inc., Oxonica Plc, Par Pharm...
PDL BioPharma Announces First Quarter 2009 Financial Results
...tin(R) and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-La Roche Ltd., and sales of Tysabri(R), which is marketed by elan Corporation, Plc. Royalty revenues are based on fourth quarter product sales by PDL's licensees and include those for Synagis(R), which is marketed by...... Scaife held the position of Vice President of Quality and Regulatory Affairs for Nektar Therapeutics, Vice President of Global Regulatory Affairs for elan Pharmaceuticals, and various regulatory and clinical development positions for Novartis Pharma. Dr. Scaife began his career as the Regulatory and Med...
Alkemists Labs Wins Nutrition Business Journal's 2008 Industry Growth Award
...ete. "We've been planning our strategic growth for some time now and are implementing an aggressive approach to meet customer demand," says elan Sudberg, COO of Alkemists Labs. The expansion will enable the lab to approximately double the weekly sample load, with a primary emphasis on fast...Other TagsOther Contents
AndelprongACNBrushesSagittalChargerThrottleSaggitalOscillatingReamerMultisteppe20RRoboticUltramicroDFL10
(Date:6/18/2013)... 18, 2013 -- Lauren Sciences, a privately-held biotechnology ... platform technology, announced today that it was independently ... with its V-Smart Platform, and selected as a ... Group. , The report, " Early ... Emerging Companies ," features companies MCD Group independently ...
(Date:6/18/2013)... are more likely to keep their scheduled medical appointments ... feel their physician listens, explains things clearly and knows ... Johns Hopkins research suggests. , "If people feel their ... feel that doctor has their best interests at heart ... says study leader Tabor E. Flickinger, M.D., M.P.H., a ...
(Date:6/18/2013)... Obama officially declared June as Lesbian, Gay, ... despite advances in civil rights, sexual minority ... suicide than their heterosexual peers, according to ... of Missouri psychology graduate student recently published ... minority youth, which could help improve psychological ...
(Date:6/18/2013)... FDA to support the need for a blood test ... University of Rochester Medical Center just added significant evidence ... that it might be clinically useful to measure two ... M.P.H., an associate professor of Emergency Medicine at URMC, ... combination of two proteins released into the bloodstream after ...
(Date:6/18/2013)... penalties on hospitals with higher-than-expected rates of 30-day ... are evaluating the most accurate methods for tracking ... in the June issue of the Journal ... that the American College of Surgeons National Surgical ... accurate data tracking than another popular database, the ...
Breaking Medicine News(10 mins):Health News:Respect may be the key to stopping patient 'no shows' 2Health News:Sexual minority youth need specialized treatment from therapists 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 2Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 3Health News:ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions 4[0] Lauren Sciences independently recognized as a Technology Innovator in Drug Delivery with its V-Smart™ Platform, and selected as a Featured Company, in new report by MCD Group[0] Respect may be the key to stopping patient 'no shows'[0] Sexual minority youth need specialized treatment from therapists[0] New concussion data: 2 biomarkers better than 1[0] ACS NSQIP® data is more accurate than administrative data for tracking 30-day hospital readmissions
(Date:6/18/2013)... has awarded $12.7 million to match nine academic ... compounds to explore new treatments for patients in ... dystrophy and schizophrenia. The collaborative pilot initiative, called ... led by the National Center for Advancing Translational ... Fund. , The process of developing a new ...
(Date:6/18/2013)... of breast and ovarian cancers are familial in origin, ... to inherited mutations from the parents in genes such ... PARP inhibitors, which are currently in clinical trials, have ... for personalised cancer treatment, an alternative to standard chemotherapy. ... these patients generate resistance to the drug and, therefore, ...
(Date:6/17/2013)... in the U.S. exposed to high levels of air pollution ... a child with autism as women who lived in areas ... School of Public Health (HSPH). It is the first large ... across the U.S. , "Our findings raise concerns since, depending ... our study lived in areas where risk of autism was ...
Breaking Biology News(10 mins):NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |